- Home
- CTSO vs CBUS Comparison
CTSO vs CBUS Comparison
Compare CTSO & CBUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTSO
- CBUS
- Stock Information
- Founded
- CTSO 1997
- CBUS 2010
- Country
- CTSO United States
- CBUS United States
- Employees
- CTSO N/A
- CBUS N/A
- Industry
- CTSO Medical/Dental Instruments
- CBUS Agricultural Chemicals
- Sector
- CTSO Health Care
- CBUS Industrials
- Exchange
- CTSO Nasdaq
- CBUS Nasdaq
- Market Cap
- CTSO 73.5M
- CBUS 86.0M
- IPO Year
- CTSO N/A
- CBUS 2017
- Fundamental
- Price
- CTSO $1.19
- CBUS $3.05
- Analyst Decision
- CTSO Strong Buy
- CBUS Strong Buy
- Analyst Count
- CTSO 3
- CBUS 3
- Target Price
- CTSO $4.67
- CBUS $22.83
- AVG Volume (30 Days)
- CTSO 118.0K
- CBUS 343.2K
- Earning Date
- CTSO 11-07-2024
- CBUS 11-07-2024
- Dividend Yield
- CTSO N/A
- CBUS N/A
- EPS Growth
- CTSO N/A
- CBUS N/A
- EPS
- CTSO N/A
- CBUS N/A
- Revenue
- CTSO $37,159,990.00
- CBUS $2,961,000.00
- Revenue This Year
- CTSO $11.14
- CBUS $36.93
- Revenue Next Year
- CTSO $17.07
- CBUS $236.45
- P/E Ratio
- CTSO N/A
- CBUS N/A
- Revenue Growth
- CTSO 2.17
- CBUS 816.72
- 52 Week Low
- CTSO $0.70
- CBUS $2.98
- 52 Week High
- CTSO $2.15
- CBUS $23.18
- Technical
- Relative Strength Index (RSI)
- CTSO 45.86
- CBUS 30.33
- Support Level
- CTSO $1.26
- CBUS $3.09
- Resistance Level
- CTSO $1.59
- CBUS $3.75
- Average True Range (ATR)
- CTSO 0.16
- CBUS 0.38
- MACD
- CTSO -0.03
- CBUS 0.04
- Stochastic Oscillator
- CTSO 14.89
- CBUS 2.90
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales, Distributors/strategic partners, and Government segments. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.
About CBUS Cibus Inc.
Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.